Compare SNOW & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNOW | TEVA |
|---|---|---|
| Founded | 2012 | 1901 |
| Country | United States | Israel |
| Employees | N/A | 32842 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.9B | 41.6B |
| IPO Year | 2020 | N/A |
| Metric | SNOW | TEVA |
|---|---|---|
| Price | $158.14 | $34.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 43 | 8 |
| Target Price | ★ $248.62 | $38.63 |
| AVG Volume (30 Days) | ★ 6.2M | 6.1M |
| Earning Date | 05-20-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,683,946,000.00 | N/A |
| Revenue This Year | $28.57 | N/A |
| Revenue Next Year | $23.41 | $2.97 |
| P/E Ratio | ★ N/A | $28.19 |
| Revenue Growth | ★ 29.16 | N/A |
| 52 Week Low | $118.30 | $14.99 |
| 52 Week High | $280.67 | $37.35 |
| Indicator | SNOW | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 58.64 | 54.67 |
| Support Level | $155.35 | $30.53 |
| Resistance Level | $186.62 | $35.32 |
| Average True Range (ATR) | 6.71 | 1.03 |
| MACD | 2.07 | -0.05 |
| Stochastic Oscillator | 93.40 | 57.32 |
Snowflake Inc Founded in 2012, Snowflake is a fully managed platform that consolidates data hosted on different public clouds for centralized analytics and governance. Snowflakes cloud-native architecture allows users to independently scale the compute and storage layers, providing customers with optimized performance at lower costs. The companies data lake and data warehouse products support a variety of use cases, including business analytics, data engineering, and artificial intelligence. Snowflake is widely used by Fortune 2000 companies in financial services, media, and retail sectors.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.